SCHEMBL2255127

SCHEMBL2255127

COc1ccnc2nc(-c3c(F)cc(OCCF)cc3F)c(Nc3ccc4c(c3)OCCO4)n12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 13/20 0.47
▸ MAPT P10636 14/20 0.42
▸ SMN1; SMN2 Q16637 4/20 0.42
▸ TDP1 Q9NUW8 3/20 0.42
▸ KDM4E B2RXH2 2/20 0.41
▸ SYK P43405 3/20 0.41
▸ MAPK1 P28482 3/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ PKM P14618 1/20 0.40
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ GSK3B P49841 1/20 0.38
▸ LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2258225 0.92 GAA (0.47) GAAMAPTSMN1; SMN2TDP1KDM4E
SCHEMBL13474766 0.89 GAA (0.43) GAAMAPTSMN1; SMN2TDP1KDM4E
SCHEMBL2252107 0.88 GAA (0.48) GAAMAPTSMN1; SMN2TDP1KDM4E
SCHEMBL2249754 0.81 GAA (0.49) GAAMAPTSMN1; SMN2TDP1KDM4E
SCHEMBL13474718 0.81 MAPT (0.43) GAAMAPTSMN1; SMN2TDP1KDM4E
SCHEMBL2250099 0.81 MAPT (0.61) GAAMAPTSMN1; SMN2TDP1KDM4E
SCHEMBL2253035 0.81 GAA (0.49) GAAMAPTSMN1; SMN2TDP1KDM4E
SCHEMBL14016291 0.79 MAPT (0.48) GAAMAPTSMN1; SMN2TDP1KDM4E
SCHEMBL2248641 0.79 GAA (0.50) GAAMAPTSMN1; SMN2TDP1KDM4E
SCHEMBL12360703 0.79 GAA (0.50) GAAMAPTSMN1; SMN2TDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155747-B1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS GE HEALTHCARE LTD (GB) 2012-10-24 — — EP disclosed
EP-2155747-B1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS GE HEALTHCARE LTD (GB) 2012-10-24 — — EP disclosed
US-20110206607-A1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS GE HEALTHCARE LIMITED (GB) 2011-08-25 — — US disclosed
US-20110206607-A1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS GE HEALTHCARE LIMITED (GB) 2011-08-25 — — US disclosed
US-20110206607-A1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS GE HEALTHCARE LIMITED (GB) 2011-08-25 — — US disclosed
WO-2008141249-A1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS ACADIA PHARMACEUTICALS INC. (US) 2008-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110206607-A1 IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS CNR1, CNR2, GPR18 GAA 4087/4885MAPT 2915/4885SMN1; SMN2 3141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback